Clinical impact of first-line therapeutic strategies in BRAF V600E-mutant metastatic colorectal cancer: real-world evidence and prognostic insight

In this real-world cohort, chemotherapy combined with anti-VEGF provided the best survival outcomes, while <i>BRAF</i>-targeted strategies showed promising response rates. Liver involvement and poor performance status remained negative prognostic indicators. These findings support a personalized treatment approach and highlight the need for continued prospective validation.